Expertise in
18
conditions

Dr. Benjamin Garmezy

Oncology
335 24th Ave N, Ste 200, 
Nashville, TN 
Accepting New Patients
Offers Telehealth
Expertise in
18
conditions
335 24th Ave N, Ste 200, 
Nashville, TN 

Overview

Benjamin Garmezy is an Oncologist practicing medicine in Nashville, Tennessee.

Dr. Garmezy is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Choriocarcinoma, Urothelial Cancer, and Adult Soft Tissue Sarcoma.

Dr. Garmezy is board certified in The American Board Of Internal Medicine - Hematology, The American Board Of Internal Medicine - Medical Oncology, and The American Board Of Internal Medicine - Internal Medicine. He is actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 2 clinical trials. Dr. Garmezy is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in TX

Board Certifications

The American Board Of Internal Medicine - Hematology
The American Board Of Internal Medicine - Medical Oncology
The American Board Of Internal Medicine - Internal Medicine

Fellowships

University of Texas MD Anderson Cancer Center

Hospital Affiliations

Ascension Saint Thomas Hospital Midtown
Ascension Saint Thomas Hospital
Tristar Horizon Medical Center
Tristar Centennial Medical Center
Williamson Medical Center
Tristar Summit Medical Center
Tristar Southern Hills Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

SCRI Oncology Partners
335 24th Ave N, Ste 200, Nashville, TN 37203

Additional Areas of Focus

Dr. Garmezy has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors
A Phase 1, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: April 24, 2024
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

17 Total Publications

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.
Journal: Future oncology (London, England)
Published: May 16, 2026
Similar Doctors
Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

Tennessee Oncology, PLLC-#412 25th Ave

250 25th Ave N, Ste 412, 
Nashville, TN 
 (1.2 miles away)
615-986-7600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ian Flinn is an Oncologist practicing medicine in Nashville, Tennessee. Dr. Flinn is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Flinn is board certified in The American Board Of Internal Medicine - Hematology. Dr. Flinn is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

SCRI Oncology Partners

335 24th Ave N, Ste 200, 
Nashville, TN 
 (0.1 miles away)
615-329-7640
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erika Hamilton, MD, is an independent medical oncologist and hematologist at Ascension Saint Thomas in Nashville, Tennessee. Dr. Hamilton diagnoses and treats adults with cancer and focuses on managing care during and after chemotherapy, radiation therapy and surgery. Every appointment with Dr. Hamilton starts with a conversation. She takes the time to answer all your questions — big and small. Dr. Hamilton is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, Ovarian Cancer, and HER-2 Positive Breast Cancer. Dr. Hamilton is board certified in The American Board Of Internal Medicine - Medical Oncology. Dr. Hamilton is currently accepting new patients.

Expertise in
31
conditions
Expertise in
31
conditions
Referral may be required

Tennessee Oncology, PLLC-#412 25th Ave

250 25th Ave N, Ste 412, 
Nashville, TN 
 (1.2 miles away)
615-986-7600
Languages Spoken:
English, French, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jesus Berdeja is an Oncologist practicing medicine in Nashville, Tennessee. Dr. Berdeja is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration. Dr. Berdeja is board certified in The American Board Of Internal Medicine - Hematology. Dr. Berdeja is currently accepting new patients.

Frequently Asked Questions about Dr. Benjamin Garmezy

How do I make an appointment with Dr. Benjamin Garmezy?

You can book an appointment with Dr. Benjamin Garmezy by calling their office at 615-329-7640. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Benjamin Garmezy a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Benjamin Garmezy is classified as an Advanced expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Benjamin Garmezy specialize in?

While Dr. Benjamin Garmezy is a Oncology, they have specific expertise in Renal Cell Carcinoma (RCC), Choriocarcinoma, and Urothelial Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Benjamin Garmezy participate in research or clinical trials?

Yes. Dr. Benjamin Garmezy has published 17 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. Benjamin Garmezy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Benjamin Garmezy accept my insurance?

Dr. Benjamin Garmezy accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 615-329-7640 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Garmezy's expertise for a condition
ConditionClose
      View All 18 Advanced Conditions
      View All 57 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile